FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068720118> ?p ?o ?g. }

• W2068720118 endingPage "448" @default.
• W2068720118 startingPage "443" @default.
• W2068720118 abstract "Dysregulation of cyclin-dependent kinases is a hallmark of myeloma, and specifically, cdk5 inhibition can enhance the activity of proteasome inhibitors in vitro. Dinaciclib is a novel potent small molecule inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9. Patients with relapsed multiple myeloma and ≤5 prior lines of therapy, with measurable disease, were enrolled. Dinaciclib was administered on day 1 of a 21-day cycle at doses of 30 to 50 mg/m(2). Overall, 27 evaluable patients were accrued; the median number of prior therapies was 4. The dose level of 50 mg/m(2) was determined to be the maximally tolerated dose. The overall confirmed partial response rate (PR) was 3 of 27 (11%), including 1 patient at the 30 mg/m(2) dose (1 very good PR [VGPR]) and 2 patients at the 40 mg/m(2) dose (1 VGPR and 1 PR). In addition, 2 patients at the 50 mg/mg(2) dose achieved a minimal response (clinical benefit rate, 19%). Leukopenia, thrombocytopenia, gastrointestinal symptoms, alopecia, and fatigue were the most common adverse events. The current study demonstrates single agent activity of dinaciclib in relapsed myeloma, with 2 patients achieving a deep response (VGPR) and 10 patients obtaining some degree of M protein stabilization or decrease. This trial was registered at www.clinicaltrials.gov as #NCT01096342." @default.
• W2068720118 created "2016-06-24" @default.
• W2068720118 creator A5003015868 @default.
• W2068720118 creator A5022511085 @default.
• W2068720118 creator A5026574827 @default.
• W2068720118 creator A5032135930 @default.
• W2068720118 creator A5034791164 @default.
• W2068720118 creator A5042432109 @default.
• W2068720118 creator A5044733637 @default.
• W2068720118 creator A5066282840 @default.
• W2068720118 creator A5069676334 @default.
• W2068720118 creator A5091287816 @default.
• W2068720118 date "2015-01-15" @default.
• W2068720118 modified "2023-10-14" @default.
• W2068720118 title "Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma" @default.
• W2068720118 cites W1965355458 @default.
• W2068720118 cites W1988050012 @default.
• W2068720118 cites W1988265934 @default.
• W2068720118 cites W2001558395 @default.
• W2068720118 cites W2040889135 @default.
• W2068720118 cites W2041694372 @default.
• W2068720118 cites W2044436186 @default.
• W2068720118 cites W2051256348 @default.
• W2068720118 cites W2055576683 @default.
• W2068720118 cites W2055662838 @default.
• W2068720118 cites W2076028786 @default.
• W2068720118 cites W2076680628 @default.
• W2068720118 cites W2080278485 @default.
• W2068720118 cites W2111420633 @default.
• W2068720118 cites W2121619780 @default.
• W2068720118 cites W2128956884 @default.
• W2068720118 cites W2140277695 @default.
• W2068720118 cites W2140579395 @default.
• W2068720118 cites W2144002245 @default.
• W2068720118 cites W2149877193 @default.
• W2068720118 cites W2155141574 @default.
• W2068720118 cites W2155550387 @default.
• W2068720118 cites W2158608759 @default.
• W2068720118 cites W297761204 @default.
• W2068720118 cites W58113886 @default.
• W2068720118 doi "https://doi.org/10.1182/blood-2014-05-573741" @default.
• W2068720118 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4296007" @default.
• W2068720118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25395429" @default.
• W2068720118 hasPublicationYear "2015" @default.
• W2068720118 type Work @default.
• W2068720118 sameAs 2068720118 @default.
• W2068720118 citedByCount "184" @default.
• W2068720118 countsByYear W20687201182015 @default.
• W2068720118 countsByYear W20687201182016 @default.
• W2068720118 countsByYear W20687201182017 @default.
• W2068720118 countsByYear W20687201182018 @default.
• W2068720118 countsByYear W20687201182019 @default.
• W2068720118 countsByYear W20687201182020 @default.
• W2068720118 countsByYear W20687201182021 @default.
• W2068720118 countsByYear W20687201182022 @default.
• W2068720118 countsByYear W20687201182023 @default.
• W2068720118 crossrefType "journal-article" @default.
• W2068720118 hasAuthorship W2068720118A5003015868 @default.
• W2068720118 hasAuthorship W2068720118A5022511085 @default.
• W2068720118 hasAuthorship W2068720118A5026574827 @default.
• W2068720118 hasAuthorship W2068720118A5032135930 @default.
• W2068720118 hasAuthorship W2068720118A5034791164 @default.
• W2068720118 hasAuthorship W2068720118A5042432109 @default.
• W2068720118 hasAuthorship W2068720118A5044733637 @default.
• W2068720118 hasAuthorship W2068720118A5066282840 @default.
• W2068720118 hasAuthorship W2068720118A5069676334 @default.
• W2068720118 hasAuthorship W2068720118A5091287816 @default.
• W2068720118 hasBestOaLocation W20687201181 @default.
• W2068720118 hasConcept C121608353 @default.
• W2068720118 hasConcept C124320809 @default.
• W2068720118 hasConcept C126322002 @default.
• W2068720118 hasConcept C141071460 @default.
• W2068720118 hasConcept C143998085 @default.
• W2068720118 hasConcept C197934379 @default.
• W2068720118 hasConcept C2776364478 @default.
• W2068720118 hasConcept C2776694085 @default.
• W2068720118 hasConcept C2777063308 @default.
• W2068720118 hasConcept C2780873365 @default.
• W2068720118 hasConcept C29537977 @default.
• W2068720118 hasConcept C71924100 @default.
• W2068720118 hasConcept C90924648 @default.
• W2068720118 hasConcept C98274493 @default.
• W2068720118 hasConceptScore W2068720118C121608353 @default.
• W2068720118 hasConceptScore W2068720118C124320809 @default.
• W2068720118 hasConceptScore W2068720118C126322002 @default.
• W2068720118 hasConceptScore W2068720118C141071460 @default.
• W2068720118 hasConceptScore W2068720118C143998085 @default.
• W2068720118 hasConceptScore W2068720118C197934379 @default.
• W2068720118 hasConceptScore W2068720118C2776364478 @default.
• W2068720118 hasConceptScore W2068720118C2776694085 @default.
• W2068720118 hasConceptScore W2068720118C2777063308 @default.
• W2068720118 hasConceptScore W2068720118C2780873365 @default.
• W2068720118 hasConceptScore W2068720118C29537977 @default.
• W2068720118 hasConceptScore W2068720118C71924100 @default.
• W2068720118 hasConceptScore W2068720118C90924648 @default.
• W2068720118 hasConceptScore W2068720118C98274493 @default.
• W2068720118 hasIssue "3" @default.
• W2068720118 hasLocation W20687201181 @default.

• next